7 days in healthcare (December 26th, 2022-January 1st, 2023)




From the point of view of Biomedicine, it is worth noting the ambitious project of the United Kingdom “Our Future Health”, which aims to place this country at the forefront of genomic research, and which seeks to carry out genetic analyzes of 5 million adult British volunteers, then looking at the correlation with lifestyles and medical records. Undoubtedly, this project will allow us to advance a lot in the knowledge of a wide variety of diseases.

With regard to Global Health, great concern in the world, since the large number of cases in China increase the probability that new variants will appear. There is no doubt that the covid – which had appeared, artificially or naturally, in China – has entered a new phase in which the epicenter is once again China.

Regarding International Health Policy, countries are preparing to put control measures at airports and borders against travelers from China, although the ECDC sees this type of control as unfounded and the EU has not adopted a common policy. Joschka Fischer (former – German Foreign Minister) publishes an in-depth article, whose conclusion is that, in contrast to what had previously been said that authoritarian regimes that do not depend on public opinion can impose drastic and effective measures in crisis situations such as covid, experience has shown that liberal democracies are more effective than autocracies in dealing with these situations. Great controversy in the European Union over the claim of the pharmaceutical industry to agree to produce new antibiotics, under the condition of increasing the patent term of certain drugs.

If we talk about National Health Policy (Spain), Spain has approved airport control measures to control travelers from China, which will be in force between December 31, 2022 and February 15, 2023. Primary Care doctors have opposed the hiring of doctors without MIR training, since this seems more like an opportunistic measure than addressing the underlying problems of Primary Care. The central government, so little fond of publishing and preparing expert analyzes on the covid management, instead presents a self-assessment on its management. According to this report “Cumpliendo” (“Fulfilling”) 64% of the health promises have already been fulfilled and 35% are in process. Bearing in mind that none of the structural healthcare problems have been addressed (personnel regime, management model, governance, accessibility and waiting lists, etc.) this self-assessment seems to us grated on complacency and even propaganda. Unless the promises -which are said to have been fulfilled- have nothing to do with the real problems of the sector. An interesting initiative from the private sector through the IDIS Foundation, which announces the start-up of a pilot on interoperability, should be highlighted. The fact that companies that compete with each other -both from the insurance and provisioning fields- agree on the interoperability of medical records is something that deserves to be highlighted.

In the field of Companies, the American Congress has taken an unusual decision: criticize the FDA for its inadequate collaboration with Biogen for the approval of the drug against Alzheimer’s. At the national level, Atrys continues its growth, both in Spain and abroad (United Kingdom, Middle East and Latin America).


Global Health

International Health Policy

National health policy





7 days in healthcare (September 26th-October 2nd, 2022)


From the point of view of Biomedicine, to review the advances, still to be confirmed, in the treatment of two terrible diseases: ALS and Alzheimer’s.

Regarding Global Health, concerns continue about the evolution of polio, whose eradication was announced in 2019, but which is reappearing in several countries.

Regarding International health policy, it is worth noting the similarities between the covid-zero policy in China and the era of prohibition in the United States, something pointed out by The Economist. Very worrying is the “burnout” of doctors, a phenomenon highlighted by the New York Times in the United States, but which seems to be universal.

If we talk about National health policy (Spain), the debates on the Equity Law continue. The update of the RD on the minimum data set of the SNS leaves out the private sector, despite the opposition of the POP, IMAS Foundation, IDIS Foundation and ASPE. It is a modification of a 2010 RD, but in twelve years the private sector has developed a lot and it is no longer so easy to leave it out in certain decisions. The Senate rejects the PP’s motion to facilitate access to medicines and reduce the time it takes to join the SNS. Surely the motion of the PP was too vague and, at this point, it is necessary to explain very well the “what” and the “how” of any proposal.

At the corporate level, at the international level, big rise in Biogen shares, spurred by what appear to be hopeful results from its Alzheimer’s drug. At the national level, there are rumors that KKR and CVC could be trying to buy Quirónsalud, currently in the hands of the German group Fresenius, which has recently changed its CEO. The Murcian company Vócali develops the Inbox Medical software for transcription of medical reports.


Global Health

International health policy

National health policy



7 days in healthcare (August 29th-September 4th, 2022)



From the point of view of Biomedicine, the great impact of the study by scientists from the University of Oviedo, who have studied the genes of a species of jellyfish, which incorporates rejuvenation elements in its life cycle, should be highlighted.

With regard to Global Health, historical decline in life expectancy in the United States, which went to 76 years in 2021, compared to 79 in 2019. The covid, the main responsible, although not the only one. Presumably we will see a similar phenomenon in Europe and in Spain.

Regarding International health policy, both the FDA and the EMA approve the covid vaccine boosters, despite some questions that have been pointed out by the journal Science. In the UK, long waiting lists in the public sector are leading to a boom in direct payment systems for healthcare.

If we talk about national health policy (Spain), the two most relevant issues are the approval of the bill that creates the Spanish Public Health Agency, subject to hearing and public information; and the draft Law on Abortion, which has very controversial elements, such as abortion in women aged 16-18 without information or parental consent; conscientious objection for doctors (on whose regulation the WTO has ruled negatively); the obligation to carry out this practice in public centers; and the dispensing of the morning after pill. Surprising statements by the President of the Community of Madrid, who attributes the shortage of doctors to the lack of Faculties of Medicine, contrary to what had been the opinion of the State Confederation of Medical Students and the Conference of Deans of Faculties of Medicine, with the support of the Forum of the Medical Profession. And the fact that only South Korea surpasses Spain in the ratio of Faculties of Medicine per million inhabitants.

In the field of companies, health has jumped into the metaverse with a business of 5,060 million dollars, although we will have to be very attentive to what we call metatarsus. HIPRA starts a trial to study its covid vaccine as a fourth dose.


Global Health

International health policy

National health policy





7 days in healthcare (January 17-23, 2022)



From an international point of view, the article published in The Lancet should be highlighted, in which mortality due to antimicrobial resistance, one of the most important causes of death in the world, is analyzed at a global level. Also the demand of the British Medical Journal that the scientific community have access to all the original data on the clinical trials of vaccines, since at this time these data are only accessible to employees of pharmaceutical companies. The Economist analyzes if the mandatory nature of the vaccine works, concluding that it does. It looks like all the COVID restrictions in England are going to end soon. The European Union gives more powers to the EMA, in case of having to manage future health crises.

As for the national news, the pandemic is still unchecked, in very high numbers and with high mortality; the debate on treating the covid as influenza continues, with opposing positions, those who are against it and those who defend it; the Ministry of Health wants to advance in the recertification, in dialogue with the FACME and the Organization of Medical Orders; The situation of health insurance in 2021 is presented, which did not stop growing, until the sector as a whole reached a turnover of close to 10,000 million euros; the Madrid College of Physicians signs a controversial agreement with UNIPROMEL, in theory to “defend doctors in free practice”, but, more possibly, with the intention of reinforcing the current weakened board of directors.

As far as companies are concerned, perhaps the most outstanding news is the sale by IBM of Watson Health, the artificial intelligence solution, designed to solve diagnostic and therapeutic problems, which had had so many problems in some centers such as MD Anderson from Houston. Although it was a good and ambitious idea, it was possibly ruined by short-termism, hyperselling and not taking enough into account the complexities of medicine and medical practice.


  • The Lancet publishes an article on the mortality of antimicrobial resistance. 204 countries and territories are analyzed in 2019. 4.95 million deaths from antimicrobial resistance were found in 2019. Antimicrobial resistance is one of the most important causes of death in the world (The Lancet, 20 January 22)
  • The British Medical Journal, after the Tamiflu experience, asks that the original data (raw data) from the clinical trials of vaccines be accessible to all researchers, not just those from the pharmaceutical industry, as is the case now (BMJ, January 19, 22)
  • The WHO gives the green light to the wider use of the third dose against COVID (FT, January 21, 22)
  • The fourth dose of the vaccine, infective in the extension of the “ómicron” variant, according to an Israeli study (FT, January 18, 22)
  • The Economist analyzes if the compulsory nature of the vaccine works. After analyzing the cases of Canada, France, Italy and Germany, he concludes that it works (The Economist, January 22, 22)
  • The covid passport strengthens the economy and vaccination (FT, January 18, 22)
  • Bill Gates warns against a pandemic potentially worse than COVID and calls on governments to spend billions of dollars to prevent it. He also says that this effort can contribute to improving the prevention and treatment of current extended diseases: HIV, tuberculosis, malaria (FT, January 19, 22)
  • All restrictions in England may end in March, according to the British Prime Minister’s plans (The Guardian, 17 January 22)
  • The EU approves the reform that gives more powers to the EMA in the management of future health crises (The Objective, 20 January 22)
  • Italy registers an increase in vaccination, after making it mandatory for those over 50 years of age (El País, January 17, 22)


  • Situation of the pandemic

o COVID, still unchecked, breaks a new record of 3,418 cases per 100,000 inhabitants (El País, January 21, 22)

o The ICUs are at the limit of their structural capacity but far from the worst moments (El País, January 17, 22)

  • Debate about dealing with the covid as if were “flu”

o Two opposing positions:

 “Gripalizing the covid or how to believe we are winners”, article by Santiago Cervera, January 15, 22)

 Antonio Zapatero is committed to self-care and not to restrictions (El Español, January 17, 22)

  • Sick leave

o Processed 21,000 sick leaves and registrations in Madrid in the first days of the new system (El País, January 20, 22)

o The doctors accuse Escrivá of violating the law with the casualties, by giving in the same act for 7 days (La Razón, January 17, 22)

  • Recertification

o The Ministry of Health commits with FACME and the WTO to promote professional recertification (Acta Sanitaria, January 21, 22)

  • Situation schools

o The avalanche of school confinements puts families on the ropes (El País, January 21, 22)

  • Health insurance

o Health insurance grows by 4.93% in 2021 and totals 9,849 million euros (Acta Sanitaria, January 18, 22)

o According to forecasts by Javier Murillo, health insurance will grow in 2022 by around 5.5-6% (presentation at ICEA)

o MJ Montero (Finance Minister): great support for the MUFACE system (MUFACE Magazine, nº 252, winter 2021)

  • Other issues

o Organ transplants overcome the slump of 2020 and grow 8% in 2021 (El País, January 21, 22)

o Argimón presents the 2021-2025 health plan (Consalud, January 20, 22)

o Health, forced by Transparency to deliver to Farmaindustria the minutes of the Pharmacy Commission of the Interterritorial Council (diariofarma, January 16, 22)

o The MIR exam will bring together candidates from 4 continents and 88 countries (redacción Médica, January 20, 22)

o The Madrid College of Physicians signs an agreement with UNIPROMEL, “to defend free practice physicians” (Official Note ICOMEM, January 21, 22)

o Health awards 81 linear accelerators, in compliance with the INVEAT plan, three lots: Ab Salud, Varian and Elekta (ConSalud, January 18, 22)


  • IBM sells Watson Health to an investment firm. The sale was preceded by resounding failures of this artificial intelligence tool for medical diagnosis and treatment (WSJ, January 21, 22)
  • Moderna intends to launch a joint COVID-flu vaccine in two years (The Guardian, January 17, 22)
  • Djokovic has 80% of the shares in a Danish biotech firm (QuantBioRes) that intends to release a vaccine against COVID (The Guardian, January 19, 22)
  • Pfizer becomes the largest provider of the pandemic and it is estimated that it will double its income (, January 17, 22)
  • Pfizer, AstraZeneca and the Chinese Sinopharm and Sinovac will manufacture 70% of the COVID vaccines (CincoDías, January 20, 22)
  • Merck entrusts the manufacture of its pill against COVID to 27 manufacturers (PlantaDoce, January 20, 22)
  • More than 100 laboratories in Asia and Africa could manufacture vaccines for Pfizer and Moderna (El Independiente, January 19, 22)
  • The “telecos” take advantage of the pandemic to add clients in telemedicine (El Independiente, January 19, 22)
  • AstraZeneca, the most widely used COVID vaccine in the world that is no longer administered in Spain (El Español, January 21, 22)
  • St John of God (important hospital network in Spain, until now divided into three “provinces”) consolidates its management structure at the national level (Acta Sanitaria, January 20, 22)
  • Acciona, Sacyr and OHLA bid for a new hospital in Chile for 265 million euros (PlantaDoce, January 16, 22)
  • Dental Residency, objective by 2022 to double billing and provide coverage to 250,000 residents (PlantaDoce, January 20, 22)
  • The EMA asks HIPRA to show greater efficiency than Pfizer, if it wants to be part of the European Union’s portfolio (El Economista, January 18, 22)
  • HIPRA will carry out the last clinical trial of its vaccine at HM Hospitals (El Economista, January 17, 22).
  • Viamed is preparing an offer for one of the “Catholic” hospitals in Madrid: San Francisco and Beata María Ana (Sanifax, January 21, 22)
  • ASISA renews its Board of Directors with three members, one internal and two independent directors (Europa Press, January 20, 22)
  • Mercadona offered the Government to sell tests in its establishments at 2.90 euros. The Government preferred to keep pharmacies as the only test point of sale (Sanifax, January 20, 22)
  • Lilly publishes an overview of start ups in health in Spain (Lilly, January 22)

7 days in healthcare (January 3-9, 2022)



From an international point of view, perhaps the most striking thing is the great global expansion of COVID, particularly of the “omicron” variant, with a record number of infections in the United States, of more than one million a day.

As for national news, official policy continues to trust everything to vaccination, avoiding other measures that may have certain political costs. The problem is the number of deaths, the collapse of the health system (which affects not only COVID cases, but the rest of the patients) and the large number of sick leave. The only measure at the national level is the obligation of the mask outdoors (about whose effectiveness many doubt), without addressing the need to control the aeration of premises based on CO2 meters; the avoidance of crowds; considering the mandatory nature of the vaccine for certain groups (health workers, teachers, etc.); the more agile activation of the third dose; ensuring the existence of antigen tests and regulating their price; the management of sick leaves in another more agile way, in such a way that Primary Care no longer completely collapses; and, ensuring the purchase and accessibility of new drugs against COVID.

Regarding company news, to highlight the record sale of 7 million antigen tests by pharmacies in the week of Christmas; and the great news that the Spanish HIPRA vaccine may be present in the second quarter of year 22.


  • 5 key articles published in JAMA on January 6: 1. A National Strategy for the New Normal of Life with Covid; 2. A National Strategy for COVID-19: Testing, Surveillance and Mitigation Strategies; 3. A National Strategy for COVID-19 Medical Countermeasures: Vaccines and Therapeutics; 4. The First 2 Years of COVID-19: Lessons to Improve Preparedness for the Next Pandemic; 5. The Pandemic Preparedness Program: Reimagining Public Health (JAMA, 6 at 22)
  • Deloitte publishes a document with the six major topics that will be present in health in 2022: 1. Health equity; 2. Corporate Social Responsibility: 3. Mental health and well-being; 4. Digital transformation and impact on delivery models; 4. The future of medical science; 5. Public Health, reimagined (Deloitte,
  • The Lancet identifies humanitarian needs by 2022, the number of people in need of humanitarian assistance will rise in 2022 to 274 million, from 235 million in 2021 (The Lancet, Jan 8, 22)
  • Peter Singer, possibly the most famous bioethicist in the world, says that, in the face of a shortage of ICU beds, according to him, vaccinated people would have a preference (Project Syndicate, 5 at 22)
  • The USA reports a record number of infections throughout the pandemic, more than a million a day (FT, 4 in 22)
  • Italy declares COVID vaccination mandatory for those over 50 (The Guardian, 5 at 22)
  • A Chinese city of 1.2 million inhabitants, in confinement, before the appearance of three cases (The Guardian, 4 in 22)
  • Israel announces vaccination with a fourth dose for those over 60 years (Vozpópuli, 2 in 22)
  • The WHO follows the new IHU variant identified in France but states that it is not circulating very actively (El Mundo, 6 in 21)
  • More patients and fewer professionals push New York hospitals to the limit (NYT, 7 at 22)
  • Military deployed to London hospitals, to compensate for the absence of personnel (The Guardian, 7 at 22)
  • The French presidency of the European Union (first semester of 2022), intends to take steps in promoting the “European Health Union”, strengthening the ECDC, EMA and HERA (ConSalud, Jan 9, 22)


  • “Spain, sick, resigned and incredulous”, hard and accurate article by José Antonio Zarzalejos, on the absence of a strategy against COVID-19. He accuses of attempts to trivialize the attitude of the Spanish authorities (both national and regional), trusting everything to vaccination, but not adopting other measures, as in other countries. It has not even debureaucratized sick leave. The government gets out of the way, individualizing the response to the pandemic. (El Confidencial, 8 at 22)
  • The number of cases in Spain reaches record figures throughout the pandemic (2,722 per 100,000 inhabitants in the last 14 days). The numbers of admitted and patients in ICU are somewhat lower than in other waves, but also worrying (Ministry of Health, Update no 537. Coronavirus disease (COVID-19). 01.07.2022)
  • Between the need to care for COVID, the administrative role for sick leaves and the personnel’s own dismissals, the «omicron» variant pushes Primary Care to the limit (El País, Jan 3, 22)
  • ICUs are as full as a year ago, with 10 times more incidence (El Español, 6 in 22)
  • More than a million children between 5 and 11 years old already have the first dose of the vaccine (El Confidencial, 4 in 22)
  • Spain is late in the purchase of new anti-COVID drugs, while other European countries already have reservations, but in Spain this was delegated to the autonomous regions (La Razón, 7 at 22)
  • The return to classes will be face-to-face at all stages from January 10, agreement of the Interterritorial Council (Sanitary Act, 4 at 22)
  • Health and communities say that at the school level, entire groups will only quarantine if there are five or more cases (El País, 7 out of 22)
  • Raise to five the positives in a classroom to confine them, something without scientific evidence, says the Spanish Association of Pediatrics (7 in 21)
  • Flurona, first cases of simultaneous influenza and covid infections in Spain (Expansión, 3 in 22)
  • December closes with 240,000 sick leave due to COVID, three times more than in November (CincoDías, 4 in 22)
  • A CIS study shows (?) That 55% of Spaniards are not being greatly affected by the pandemic (Vozpópuli, 3 in 22)
  • Great step back from smoking in Spain, they start smoking again like a decade ago (El Periódico de España, 4 at 22)
  • Almost forty organizations reject the Madrid Omnibus Law, published on December 23 and with a 7-day hearing procedure, between Christmas Eve and New Year’s Eve, modifying 33 laws and 5 decrees in force in the Community of Madrid (Acta Sanitaria, 4 Jan 22)


  • Pharmacies sold a record 7 million antigen tests in the week of Christmas (CincoDías, 4 in 22) and in six months they have sold more than 21 million tests (El Debate, 6 in 22)
  • According to the Minister of Health, antigen tests will only be sold in pharmacies, contrary to what happens in other European countries (Diariofarma, 4 in 22)
  • Private hospitals denounce the Xunta for not compensating for its intervention during the state of alarm (La Voz de Galicia, 4 at 22)
  • HIPRA, the Spanish vaccine, already has a release date in the second quarter of 2022 (La Razón, 4 at 22)
  • The vaccine triggers the value of Novavax, Moderna, BioNTech and Pfizer on the stock market (Expansión, 6 Jan 22)
  • Pfizer and BioNTech will search for a vaccine against herpes zoster (CincoDías, 5 en 22)
  • The German Synlab buys the Valencian company Sistemas Genónicos, belonging to the Ascires group (Expansión, 7 at 22)
  • Rovi, newcomer and favorite among IBEX stocks (CincoDías, 9 at 22)
  • Telefónica has more than 50,000 clients in its telemedicine service (The Objective, 6 in 22)

7 days in healthcare (1-7 november, 2021)




From an international point of view, to highlight something we knew: that WHO, in its current configuration, is not prepared for global health challenges. However, this finding is important in the article in the British Medical Journal by Anthony Costello. Europe, once again in the center of expansion of the pandemic. The decision of the North American Democrats to reduce the price of medicines, via the negotiation in Medicare, is very far-reaching. This decision, if applied, will have major consequences for the entire pharmaceutical industry globally.

At the national level, to highlight the article in The Lancet, which says that Spain could have achieved group immunity. For the rest, the incidence of COVID continues to grow in our country, although it does not reach, by far, those of other European countries. Waiting lists are a big concern throughout Spain. Controversy over the new Equity, Universalization and Cohesion Law. Podemos wants to take advantage of it to repeal Law 15/1997, which allows the outsourcing of health services.

As a business activity, to highlight the two new antivirals against covid-19, one from Merck and the other from Pfizer. Merck has released the patent so that it can be used widely in developing countries. Novartis dissociates itself from Roche, selling it its 33% stake in the latter company.


  • The WHO, in its current configuration, is not ready for its purpose, but is limited by lack of funds and political interference, and this has been demonstrated in this pandemic that has produced more than 18 million deaths, writes the economist Anthony Costello in the British Medical Journal (BMJ, 3 Nov 21)
  • Europe once again at the center of the covid pandemic, says WHO, (The Guardian, 4 Nov 21)
  • The WHO warns of the increase in deaths from covid in 56 countries, and insists that vaccine manufacturers have not done their job well (ConSalud, 5 Nov 21)
  • Democrats in the United States reach an agreement to reduce the price of drugs, allowing the government to negotiate the price of Medicare drugs. The United States pays three times more for many drugs than Europe, according to a study by the Brookings Institution. Initially, the measure will be launched with the 12 most expensive drugs (FT, 2 Nov 21)
  • The fourth wave continues to beat the record of infections in Greece, with almost 7,000 daily (El Confidencial, 6 Nov 21)
  • Excess mortality grows in Russia, since the beginning of the pandemic (FT, 2 Nov 21)
  • The management of the pandemic leaves a trail of investigated political leaders: Brazil, France, Italy, Austria, India, … (El Debate, 2 Nov 21)
  • India’s successes against covid are analyzed: more than half of Indians have received at least one dose of the vaccine. 6 million are vaccinated every day (The Economist, 29 Oct 21)



  • The Lancet suggests that Spain could have achieved group immunity. They are based on the high infections and the high percentage of vaccination (La Razón, 3 Nov 21)
  • The incidence of covid rises more than two points, to 53.7 cases per 100,000 inhabitants (El País, 5 Nov 21)
  • Madrid for the first time exceeds half a million patients to see the specialist. Experts warn that the pandemic has generated in Spain a dammed demand that will emerge in the coming semesters (El País, 5 Nov 21)
  • Spain, one of the five countries in which Covid-19 caused the greatest loss in life expectancy, according to a study published by the British Medical Journal (ABC, 3 Nov 21)
  • The Health Ministry sells a million vaccines to Australia, New Zealand and Paraguay, before they expire (El Español, 2 Nov 21)
  • The WHO requests to increase oral public coverage in Spain (Health Act. The proposal receives the support of the General Council of Dentists (Health Act, 5 Nov 21)
  • Podemos will not support the Darias Equity Law. The Ministry wants to promote a Law of Equity, Universality and Cohesion and Podemos does not support it by not repealing Law 15/1997, which allows the outsourcing of health services (ConSalud, 5 Nov 21)
  • The Health Ministry seeks location for its strategic reserve of covid material (El Periódico de España, 5 Nov 21)



  • Merck drug effective to treat covid-19. The drug is an oral antiviral, called molnupiravir, and has already been approved by the British Agency. It has been launched by Merck and Ridbback Biotherapeutics, a Florida-based biotech. The drug is indicated for the unvaccinated and for those vaccinated who develop the disease. The treatment will be worth US $ 700 in developed countries. Merck will allow the development of generics in 105 countries (The Economist, 4 Nov 21)
  • Alphabet, Google’s parent company, launches an AI company, Isomorphic Labs, for the discovery of new drugs. It will work together with DeepMinds, Google’s AI company (FT, 4 Nov 21)
  • Pfizer increases the sales forecast of its covid vaccine in 2021 to 36,000 million US $ (FT, 2 Nov 21)
  • Biogroup, a bioanalysis group piloted by Stéphane Eimer and with a presence in Belgium, Luxembourg and the United Kingdom, enters the Iberian Peninsula with the purchase of Cerba Internacional and Analiza (both owned by Marcelo Weisz). ASISA will retain its 50% stake in Analiza (Les Echos, 4 Nov 21)
  • Novavax, a protein-based American covid-19 vaccine, receives its first approval in Indonesia. May promote immunization in developing countries. An application for authorization has also been sent to Canada, the United Kingdom and the European Union (FT, 1 Nov 21)
  • Pfizer announces an antiviral pill (Paxlovid) that prevents 89% of hospitalizations and deaths from covid (El País, 5 Nov 21)
  • The Valencian government will propose to the Data Protection Agency a sanction to Ribera for withholding data from the Torrevieja hospital (, Nov 4 21)
  • Centene closes the year of the coronavirus with losses in its health adventure in Spain (Nov 6, 21)
  • “Son Espases”: the macro-investigation on the concession to OHL of this hospital in the Balearic Islands, which links the Balearic Islands with the illegal financing of the PP (, Nov 5, 21)
  • Novartis sells its 33% stake to Roche for more than US $ 20 billion. A relationship of more than twenty years between the two companies is ended (PlantaDoce, Nov 4, 21)
  • MD Anderson launches a clinical trials unit (PlantaDoce, 3 Nov 21)
  • Eugin expands through Canada and acquires the fertility centers of Trio Fertility (PlantaDoce, 2 Nov 21)
  • Affidea, a European provider of diagnostic imaging, outpatient services and cancer care, expands in Spain and Northern Ireland with two new acquisitions (PlantaDoce, Nov 3, 21)
  • The biotechnology company of Spanish origin Aura Biosciences, jumps to the Nasdaq (PlantaDoce, 3 Nov 21)
  • Rovi doubles its profit in the first nine months of 2021, to 99 million (PlantaDoce, 3 Nov 21)